Seres Therapeutics to Present at H.C. Wainwright Conference

CAMBRIDGE, Mass., Sept. 01, 2026 /CourierPR/ -- Seres Therapeutics, a leading live biotherapeutics company, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, to be held in New York on September 15, 2026. The company’s management will present a comprehensive overview of its operations at 2 p.m. Eastern Time, offering investors and stakeholders a detailed update on its innovative products and strategic initiatives.

The presentation will be broadcast live via webcast, accessible at the conference's designated link. A replay will also be available on the “Events and Presentations” section of Seres Therapeutics' website following the event, providing attendees with an opportunity to review the content at their convenience.

Seres Therapeutics focuses on developing novel live biotherapeutics to address unmet needs in oncology and inflammatory and immune diseases. The company’s biotherapeutics are designed to modulate host function, protecting and improving the mucosal epithelial barrier integrity, inducing immune homeostasis and tolerance, and preventing the colonization and overgrowth of pathogens in the gastrointestinal tract.

The company has a robust pipeline, with several products in various stages of development. SER-155, an investigational multi-strain biotherapeutic, has received Breakthrough Therapy and Fast Track designations. Currently in Phase 2 readiness, SER-155 is being advanced for the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants. Additionally, the therapy is being explored as a potential immunosuppressive-free alternative for immune checkpoint inhibitor-related enterocolitis (irEC), enabling patients to continue their cancer immunotherapy treatments.

Recent positive results from an investigator-sponsored trial have prompted Seres to evaluate the design of a Phase 2 study for SER-155 in irEC. The company is also progressing IND-enabling studies for SER-603, a biotherapeutic in development for inflammatory bowel disease.

“Seres Therapeutics continues to innovate and advance our pipeline of biotherapeutics to meet the pressing needs of patients,” said Dr. Carlo Tanzi, Chief Strategy and Business Officer at Seres Therapeutics. “Our participation in the H.C. Wainwright conference is an important opportunity to share our latest developments and engage with investors and partners.”

The company’s biotherapeutic products, such as VOWST™, which was previously divested to Nestlé Health Science, have demonstrated significant promise in addressing unmet medical needs. SER-155’s potential as an effective treatment for irEC and its Phase 2 readiness underscores the company’s commitment to advancing its therapies to benefit patients.